Immune checkpoint inhibitors (ICIs) can elicit toxicities by inhibiting negative regulators of
adaptive immunity. Sometimes, management of toxicities may require systemic glucocorticoids…

The role of CTLA-4 in negative regulation of T-cell mediated immune response is particularly
well established. Much less is known about its expression and function in tumour cells, and …

HER2 targeted therapies have significantly improved prognosis of HER2-positive breast
and gastric cancer. HER2 overexpression and mutation is the pathogenic driver in non-small …

Background Concomitant medications are known to impact on clinical outcomes of patients
treated with immune checkpoint inhibitors (ICIs). We aimed weighing the role of different …

Non-small cell lung cancer is one leading cause of death worldwide, and patients would
greatly benefit from an early diagnosis. Since targeted and immunotherapies have emerged as …

Background Single-agent pembrolizumab represents the standard first-line option for metastatic
non-small-cell lung cancer (NSCLC) patients with a PD-L1 (programmed death-ligand 1…

Original research: First-line nivolumab plus ipilimumab for metastatic non-small cell lung
cancer, including patients with ECOG performance status 2 and other special populations: …

Background Rare cases of severe myocarditis are reported during treatment with nivolumab.
Troponin, a biomarker of cardiac damage, is a key component of the diagnostic workup of …

The treatment of non-small cell lung cancer (NSCLC) has changed dramatically with the
advent of immune checkpoint inhibitors (ICIs). Despite encouraging results, their efficacy …

Circulating tumor cells (CTCs) are cells spread from the primary tumor into the bloodstream
that might represent an important biomarker in lung cancer. The prognosis of patients …